3C
IRWD icon

361 Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

361 Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-114,041
Closed -$1.52M – 337
2019
Q4 		$1.52M Buy
+114,041
New +$1.26M 0.42% 61

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

361 Capital's IRWD Position: Q1 2020 in Review

361 Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2020, closing a stake of 114,041 shares — an estimated $1.52M sold.

361 Capital first reported a position in IRWD in Q4 2019 and held it in 1 quarter. The position peaked at $1.52M in Q4 2019. 193 funds tracked by Wall St. Rank hold IRWD as of Q1 2020.

  • 361 Capital reported no remaining Ironwood Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • 361 Capital sold 114,041 Ironwood Pharmaceuticals shares in Q1 2020, an estimated $1.52M.
  • 361 Capital first reported a position in Ironwood Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • 361 Capital's Ironwood Pharmaceuticals position peaked at $1.52M in Q4 2019.
  • 193 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.